BRIEF-Gensight To Submit Lumevoq For Marketing Authorisation in EU - Reuters - 1 minute read
July 6 (Reuters) - GENSIGHT BIOLOGICS SA:* GENSIGHT BIOLOGICS REPORTS SUSTAINED EFFICACY AND SAFETY AMONG LHON PATIENTS THREE YEARS AFTER LUMEVOQ® TREATMENT
* NEW DATA WILL REINFORCE SUBMISSION OF LUMEVOQ® FOR MARKETING AUTHORIZATION IN EUROPEAN UNION, WHICH IT INTENDS TO FILE IN SEPTEMBER 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Source: Reuters
Powered by NewsAPI.org